Venus Remedies

By Rishika Sadam

June 12 (Reuters) - India's drug price regulator raised ceiling rates for two key platinum-based cancer drugs by 50% after a surge in raw material costs triggered widespread shortages, according to a government notification seen by Reuters.

The National Pharmaceutical Pricing Authority invoked special provisions to raise rates for the drugs after receiving federal government approval citing public interest, according to the notification dated June 11.

Patients in the world's most populous country have been grappling with shortages of platinum-based cancer drugs cisplatin and carboplatin, as hospitals, especially government-run ​facilities, run short.

The prices of the drugs, used to treat ovarian, lung and bladder cancers, are capped and controlled by the government.

The ceiling rate for cisplatin was raised to 10.89 rupees ($0.1144) per ml from 7.26 rupees, while that for carboplatin was increased to 90.74 rupees ($0.9530) per ml from 60.49 rupees excluding taxes, the notification showed.

"... The authority noted concerns regarding shortage and supply disruptions of carboplatin and cisplatin formulations, which are essential oncology medicines used in the treatment of various cancers," the NPPA said, adding that their uninterrupted availability is critical for public health.

The drugs are manufactured by several companies, including Cipla CIPL.NS, Intas Pharmaceuticals and oncology-focused firms such as Naprod Life Sciences and Venus Remedies VENR.NS.

The increase is a one-time revision and will be reviewed after six months, the NPPA said.
India is heavily dependent on imported platinum, which is used in industries ranging from automobiles and jewellery to chemicals and pharmaceuticals.

Supplies of the white metal from key producers such as South Africa have dwindled amid soaring costs, while the Middle East conflict has further disrupted supply chains and raised manufacturing expenses, doctors and industry executives have told Reuters.

The increase on drug price caps offers relief to medicine makers who had temporarily halted production as platinum prices more than doubled amid tight supplies, strong demand and shrinking inventories.

($1 = 95.2150 Indian rupees)

(Reporting by Rishika Sadam, Additional reporting by Abhinav Parmar in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected]))

** Shares of Venus Remedies VENR.NS rise to exchange-allowed maximum of 5% to 1,633.50 rupees

** Pharmaceuticals co secures renewal of in-house research & development recognition from the Department of Scientific and Industrial Research (DSIR)

** Adds, recognition supports Venus Medicine Research Centre's ongoing work in antimicrobial resistance, including development of VRP-034, a novel polymyxin B formulation

** YTD, VENR has more than doubled

(Reporting by Vijay Malkar)

(([email protected];))

May 22 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD - RECEIVES SAUDI FDA APPROVAL FOR PLERIXAFOR

Source text: ID:nBSE70d2Vj

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise 5% to 820.6 rupees, highest in over a month

** Pharma co's Q3 consol net profit rises 30.5% Y/Y, helped by smaller expenses; rev up 2%

** Stock rose 140% in 2025

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Jan 8 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD- RECEIVED MARKETING AUTHORISATION IN INDONESIA FOR ITS ANTIBIOTIC COMBINATION CEFTAZIDIME + AVIBACTAM

Source text: ID:nBSE98GBsr

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 17.21% to 426 rupees, highest since Aug 2024

** Stock last up 11.6%; trading volume at ~15x the 30-day avg, with stock set for most active session since Feb 6

** Pharma firm's March-qtr net profit doubles to 210 mln rupees ($2.5 mln); rev little changed; total costs fall 6%

** Stock now up ~14 YTD

($1 = 85.3500 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Venus Remedies VENR.NS jump 9.2% to 341.50 rupees, set for second-best day this year

** Drugmaker gets U.S. FDA nod to use its anti-microbial resistance therapy, VRP-034

** VRP-034 used for treating injury to kidney caused by polymyxin-based therapies

** Over 197,000 shares traded, 4.2x the 30-day avg volume

** Stock has risen 7.3% so far this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Feb 25 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURES EXCLUSIVE IN-LICENSING RIGHTS FROM INFEX THERAPEUTICS

• SECURES EXCLUSIVE IN-LICENSING RIGHTS TO DEVELOP, COMMERCIALIZE MET-X IN INDIA

Source text: ID:nBSE7MjRrY

Further company coverage: VENR.NS

(([email protected];;))

** Venus Remedies' stock VENR.NS jump as much as 12.5% to 332.4 rupees; biggest intraday gain since mid-June

** Stock last up ~8% after pharma co renews European Good Manufacturing Practices (GMP) certification for Portugal plant

** Stock on track to log busiest trading session since early-Dec, with volume 3.5x the 30-day avg

** It lost ~22% in 2024 vs 124% gains in 2023

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Jan 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• RENEWS EU GMP CERTIFICATION

Source text: ID:nBSEbnVnH0

Further company coverage: VENR.NS

(([email protected];;))

** Shares of Venus Remedies VENR.NS rise as much as 4.8% to 324.95 rupees

** Pharmaceutical co says it got good manufacturing practice (GMP) certification from Moldova, which will help Eastern European expansion

** Stock on track for a third consecutive session of gain

** More than 35,000 shares change hands, 1.5x of 30-day avg

** Stock down 21.1% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Venus Remedies VENR.NS rises 7.8% to 348.30 rupees

** Pharmaceutical co secures marketing authorization for Pemetrexed 500 mg in Philippines

** Pemetrexed is a chemotherapeutic agent widely used in treatment of lung cancer and mesothelioma

** Trading vols at 65,031, 1.8x the 30-day avg

** Stock tims YTD losses to ~14%

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 2.4% to 314 rupees

** Drug maker on Friday said it will establish a unit in Hungary via its wholly owned subsidiary Venus Pharma GmbH, Germany to enhance market presence in Eastern Europe

** Stock fell 1.5% in Nov., its fourth straight monthly fall

** Stock last up 1.4%, trimming YTD loss to 23.5%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 29 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES - APPROVED SET UP OF HUNGARY UNIT TO EXPAND EASTERN EUROPE MARKET PRESENCE

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS up as much as 5% to 395 rupees, highest since Feb 15

** Drug maker on Wednesday said it won a contract from Pan American Health Organisation for supplying essential cancer drugs to multiple Latin American countries

** Stock pares some gains; last up 2%

** Including day's gains, VENR down ~6% YTD vs 18% surge in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

** Shares of India's Venus Remedies VENR.NS rise as much as 8.7% to 385 rupees, currently up ~6%

** Pharma co receives order from United Nations Children's Fund (UNICEF) for its antibiotic drug, Ceftriaxone 1gm

** Co did not disclose financial details of the order

** Trading vols 6.2x the 30-day avg

** VENR has lost 7.8% so far this year after surging 124% in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

May 30 (Reuters) - Venus Remedies Ltd VENR.NS:

• MARCH-QUARTER CONSOL NET PROFIT 105.1 MILLION RUPEES VERSUS PROFIT 110.6 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.95 BILLION RUPEES VERSUS 1.56 BILLION RUPEES

Source text for Eikon: ID:nBSE52pZH9

Further company coverage: VENR.NS

(([email protected];))

April 1 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED 25 MILLION RUPEES AS REMAINING PART OF FIRST INCENTIVE UNDER PRODUCTION LINKED INCENTIVE SCHEME

Source text for Eikon: ID:nBSE2q5KJm

Further company coverage: VENR.NS

(([email protected];;))

March 11 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURED GOOD MANUFACTURING PRACTICES (GMP ) APPROVAL FROM UNICEF

• MANUFACTURING UNIT IN BADDI APPROVED TO SUPPLY UNICEF WITH CEPHALOSPORIN ANTIBIOTICS

Source text for Eikon: ID:nBSE5jR9WN

Further company coverage: VENR.NS

(([email protected];))

March 8 (Reuters) - Venus Remedies Ltd VENR.NS:

• RECEIVES MARKETING AUTHORIZATIONS FOR ONCOLOGY DRUGS IN UKRAINE

Source text for Eikon: ID:nBSE1ZJB1N

Further company coverage: VENR.NS

(([email protected];))

March 6 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED ITS FIRST DISBURSEMENT OF 75 MILLION RUPEES UNDER PRODUCTION LINKED INCENTIVE SCHEME

Further company coverage: VENR.NS

(([email protected];))

Feb 14 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD DEC-QUARTER CONSOL NET PROFIT 68.5 MILLION RUPEES VERSUS 32.9 MILLION RUPEES

• VENUS REMEDIES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.17 BILLION RUPEES

Source text for Eikon: ID:nBSE3vZ8DB

Further company coverage: VENR.NS

(([email protected];))

Jan 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LIMITED ATTAINS GMP CERTIFICATION FROM LIBYA

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 4.18% to 425 rupees; stock last up 3.2%

** Pharma company receives new marketing authorizations for two drugs in Malta, Europe

** Approvals to help in expanding global reach, says VENR

** Trading volume is 123,997 shares as of 12:05 p.m. IST, 1.1x the 30-day avg - LSEG data

** VENR shares up 4.4% in January so far, after jumping 124.32% in 2023

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Dec 21 (Reuters) - Venus Remedies Ltd VENR.NS:

• ACHIEVES MARKETING AUTHORIZATIONS FOR DOCETAXEL IN ISRAEL AND CYTARABINE IN COLOMBIA

Source text for Eikon: ID:nBSE1gSKBR

Further company coverage: VENR.NS

(([email protected];;))

Dec 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• FORAYS INTO WELLNESS ARENA

Further company coverage: VENR.NS

(([email protected];))

Dec 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD - SUCCESSFULLY OBTAINED THREE NEW MARKETING AUTHORIZATIONS FOR ENOXAPARIN FROM BAHRAIN

Source text for Eikon: ID:nBSE6jNMDN

Further company coverage: VENR.NS

(([email protected];;))

Dec 5 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES GRANTED MARKET AUTHORIZATION FOR ENOXAPARIN IN AZERBAIJAN

Source text for Eikon: ID:nBSEQjGk2

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS up as much as 4.9% at 405 rupees

** Pharmaceutical formulations maker receives marketing authorisation for osteoporosis drug Zoledronic Acid and chemotherapy medicine Paclitaxel in Phillipines

** VENR also gets marketing authorisation for cancer drug Bleomycin in Saudi Arabia

** Over 164,000 shares traded, 0.9x the 30-day moving average

** Stock more than doubled so far this year

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Nov 9 (Reuters) - Venus Remedies Ltd VENR.NS:

• INDIA'S VENUS REMEDIES LTD SEPT-QUARTER CONSOL NET PROFIT 99.4 MILLION RUPEES VERSUS PROFIT 53.3 MILLION RUPEES

• VENUS REMEDIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.68 BILLION RUPEES VERSUS 1.40 BILLION RUPEES

Source text for Eikon: ID:nNSE1SXtMd

Further company coverage: VENR.NS

(([email protected];))